|
Advancing Nitrosamine Analysis: USP Frameworks and LC-MS/MS Solutions
|
|
1
|
300
|
June 19, 2026
|
|
Why is NMEA associated with Amphotericin B? (Appendix 1 March 2026 Update)
|
|
3
|
276
|
June 19, 2026
|
|
Nitrosamine risk assessment in early clinical development
|
|
0
|
204
|
June 17, 2026
|
|
N-nitroso-Duloxetine recall back in the news!
|
|
20
|
5598
|
June 17, 2026
|
|
Application of read-across to data-poor N-nitrosamines: N-nitroso-ulifloxacin, a case study-Pub
|
|
1
|
157
|
June 16, 2026
|
|
Calculation of the Maximum Daily Dose (MDD) in Mouthwash Products
|
|
3
|
247
|
June 16, 2026
|
|
Rupatadine related Nitrosamine
|
|
1
|
125
|
June 15, 2026
|
|
EMA - Appendix 1 - Update
|
|
94
|
10208
|
June 15, 2026
|
|
Finasteride NDSRI
|
|
2
|
174
|
June 15, 2026
|
|
Advancing Generic Drug Development: Translating Science to Approval 2025
|
|
3
|
534
|
June 11, 2026
|
|
Fiscal Year 2026 Generic Drug Science and Research Initiatives Public Workshop
|
|
6
|
381
|
June 8, 2026
|
|
N-Nitroso Vonoprazan impurity peak area variation observed during drug product analysis by LCMS
|
|
1
|
157
|
June 8, 2026
|
|
Upcoming EMA Q&A for other nitrosocompounds
|
|
3
|
468
|
June 5, 2026
|
|
The in vitro alkaline comet assay with liver models as a complementary tool for genotoxicity assessment of N-nitrosamines -Pub
|
|
0
|
91
|
June 3, 2026
|
|
👨💻 Expand the analytical toolkit for comprehensive detection of nitrosamines using SIFT-MS
|
|
0
|
126
|
June 2, 2026
|
|
An updated version of Health Canada's Guidance on nitrosamine impurities in medications(Update May 29, 2026)
|
|
0
|
318
|
June 2, 2026
|
|
MS Method Development Criterias?
|
|
1
|
175
|
June 2, 2026
|
|
For anyone attending AAPS Summer Scientific Forum
|
|
1
|
137
|
June 1, 2026
|
|
Analysis of Nitrite in Pharmaceutical Excipients: A Multi‑Laboratory Comparative Study - PUB
|
|
3
|
472
|
June 1, 2026
|
|
EDTA-Related Nitrosamine Impurities: Two Critical Pain Points in Pharma R&D
|
|
5
|
473
|
June 1, 2026
|
|
Understanding In Vitro Nitrosamine Formation During Sample Preparation
|
|
4
|
302
|
June 1, 2026
|
|
Published limit for N-Nitroso-Vonoprazan
|
|
3
|
512
|
May 29, 2026
|
|
📣 Theoretical and Experimental Assessment of Nitrosamine Risk in Industrial Solvent Recovery -Pub
|
|
3
|
549
|
May 29, 2026
|
|
Simulation of nitrosamine drug substance-related impurities from secondary amine-related impurities in approved human drug products -Pub
|
|
4
|
412
|
May 27, 2026
|
|
Why EMA still assigns AI limits (CPCA) for nitrosamines in oncology drugs
|
|
7
|
470
|
May 27, 2026
|
|
Solution stability of NDSRI
|
|
8
|
408
|
May 25, 2026
|
|
Nitrite in Amines
|
|
14
|
1040
|
May 21, 2026
|
|
N-Nitroso Perindopril Limit as NMI or 1500ng/day
|
|
3
|
261
|
May 21, 2026
|
|
Development and Validation of a Trace-Level LC–MS/MS Method for the Determination of N-Nitroso Clozapine in Clozapine Drug Substance -Pub
|
|
0
|
113
|
May 20, 2026
|
|
Strategies for Mitigating In-Source Fragmentation in NDSRI Analysis using LC-MS
|
|
4
|
2956
|
May 20, 2026
|